SOURCE XT: Results of the latest generation of the Edwards valve

The first generation of the Edwards valve was stainless steel and bovine pericardium with a profile of 22 to 24 Fr for transfemoral access and up to 33 Fr to apical access. From 2010 it became cobalt chromium bovine pericardium with a higher profile, (18-19 Fr for transfemoral and 24-26 Fr for transapical). 2,688 patients who received the valve were included in 93 centers throughout 17 countries and were followed for one year. There was a mortality rate of 2.3%, a stroke rate of 2.2%, ring rupture 0.4% and cardiac tamponade 0.9%. The need for a permanent pacemaker was 5.7% and vascular complications occurred in 11%.

Conclusion: The results with the Edwards Sapien XP valve after one year follow-up suggest a large effect in terms of symptom relief and improved quality of life with a low rate of mortality and stroke.

Stephan Windecker
2013-05-21

Original title:One-Year outcomes from the SOURCE XT post approval study. 

More articles by this author

EnligHTN: treatment of refractory hypertension by catheterization

Lowering blood pressure with renal denervation has been demonstrated in previous studies but unfortunately there was not much data regarding the reduction of clinical...

SCAAR: Heparin versus bivalirudin in patients with myocardial infarction without ST segment elevation.

We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who had not received IIBIIIB glycoprotein inhibitors and...

DESolveNx trial: Results of the new bioabsorbable platform

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This...

EUROMAX: Bivalirudin during transport to primary angioplasty

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...